Revisiting CFTR inhibition: a comparative study of CFTRinh -172 and GlyH-101 inhibitors.
OBJECTIVE
For decades, inhibitors of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel have been used as tools to investigate the role and function of CFTR conductance in cystic fibrosis research. In the early 2000s, two new and potent inhibitors of CFTR, CFTRinh -172 and GlyH-101, were described and are now widely used to inhibit specifically CFTR. However, despite some evidence, the effects of both drugs on other types of Cl(-) -conductance have been overlooked. In this context, we explore the specificity and the cellular toxicity of both inhibitors in CFTR-expressing and non-CFTR-expressing cells.


METHODS
Using patch-clamp technique, we tested the effects of CFTRinh -172 and GlyH-101 inhibitors on three distinct types of Cl(-) currents: the CFTR-like conductance, the volume-sensitive outwardly rectifying Cl(-) conductance (VSORC) and finally the Ca(2+) -dependent Cl(-) conductance (CaCC). We also explored the effect of both inhibitors on cell viability using live/dead and cell proliferation assays in two different cell lines.


RESULTS
We confirmed that these two compounds were potent inhibitors of the CFTR-mediated Cl(-) conductance. However,GlyH-101 also inhibited the VSORC conductance and the CaCC at concentrations used to inhibit CFTR. The CFTRinh -172 did not affect the CaCC but did inhibit the VSORC, at concentrations higher than 5 µM. Neither inhibitor (20 µM; 24 h exposure) affected cell viability, but both were cytotoxic at higher concentrations.


CONCLUSIONS
Both inhibitors affected Cl(-) conductances apart from CFTR. Our results provided insights into their use in mouse models.
University of Nice-Sophia Antipolis, LP2M CNRS-UMR7370, Faculté de médecine, Nice, France.
N
N
Melis
M
M
Tauc
M
M
Cougnon
S
S
Bendahhou
S
S
Giuliano
I
I
Rubera
C
C
Duranton
D000818:Animals; D001565:Benzoates / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002712:Chlorides / Q000502:physiology*; D006224:Cricetinae; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000037:antagonists & inhibitors* / Q000502:physiology; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006834:Hydrazines / Q000494:pharmacology*; D051379:Mice; D053778:Thiazolidines / Q000494:pharmacology*
C482900:3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone; D001565:Benzoates; D002712:Chlorides; D006834:Hydrazines; C548779:N-(2-naphthalenyl)-((3,5-dibromo-2,4-dihydroxyphenyl)methylene)glycine hydrazide; D053778:Thiazolidines; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D005998:Glycine
CFTR; CaCC; VSORC; chloride channel; chloride conductance; cystic fibrosis; inhibitors; patch-clamp; whole-cell